READ & LOOK AT ALL BELOW! Very Important Information is here but LOOK.
This is a simple blog and we can not organize better at this time so REVIEW ALL ARTICLES or Try Page Search to find if the information you want is here. 
AS best as possible were updating this information. If you need help, contact us directly.  All the information is here.  Understand we lost most volunteers so we are short-staffed with volunteers in Wuhan and China.

STAY HOME for 14 days in CHINA
Once you go out you risk possible exposure to the VIRUS and NOT Enough is know yet. We will update the REAL Information from Doctors & Hospital in CHINA !!!.  Look at WHO for more info. Be informed and stay safe!
FOOD & HELP BELOW.  INFORMATION FOR PPE AND SAFETY is also posted below. Mental Health, Exercise, Immune System, PPE How to, and more READ.
Reads for you FREE
Emergency Backup Blog

UPDATE COVID19 - Shanghai 2019 comprehensive treatment of coronavirus disease expert consensus Shanghai Treatment Expert Group SIFIC Infection Evidence-Based Information 6 days ago

Sunday, March 8, 2020

Open Blog Link Above CLICK TITLE >>>>>>>>>

Shanghai 2019 comprehensive treatment of coronavirus disease expert consensus
Shanghai Treatment Expert Group SIFIC Infection Evidence-Based Information 6 days ago  //
Shanghai 2019 comprehensive treatment of coronavirus disease expert consensus //

Expert Group on Clinical Treatment of New Coronary Virus Disease in Shanghai

Shanghai 2019 comprehensive treatment of coronavirus disease expert consensus
Shanghai Treatment Expert Group SIFIC Infection Evidence-Based Information 6 days ago
Shanghai 2019 comprehensive treatment of coronavirus disease expert consensus

Expert Group on Clinical Treatment of New Coronary Virus Disease in Shanghai

Coronavirus disease 2019 (COVID-19) was first reported in Wuhan, Hubei Province, on 31 December 2019. COVID-19 as a respiratory infectious disease, has been included in the "People's Republic of China Infectious Disease Prevention and Control Law" provisions of class B infectious diseases, according to class A infectious diseases management.

With the deepening of understanding of disease, all over the country in COVID-19 prevention and treatment have accumulated some experience. Shanghai new coronavirus disease clinical treatment expert group followthe national new coronavirus pneumonia diagnosis and treatment program, fully absorb the experience of domestic and foreign counterparts, in order to improve the success rate of clinical treatment and reduce the patient mortality rate of the goal, to prevent the progress of the disease, gradually reduce the proportion of seriously ill patients, improve its clinical prognosis. On the basis of continuous optimization and refinement of treatment plan, expert consensus opinions have been formed on the relevant clinical diagnosis and treatment work.

Pathogens and epidemiological characteristics

2019 New Coronavirus (2019 novel coronavirus, 2019-nCoV) is a new type of coronavirus belonging to beta. On 11 February 2020, the International Committee on Virus Classification (The International Committee on The On Taxonomy of Viruses, ICTV) named the virus Severe Acute Respiratory Syndrome Coronavirus 2 (acute acute respiratory corona syndrome 2, SARS-CoV-2).

CoVID-19 patients and asymptomatic infections can spread 2019-nCoV. The transmission by respiratory droplets is the main route of transmission and can also be transmitted through contact. There is also a risk of aerosol propagation in confined spaces. 2019-nCoV can be detected in the feces, urine and blood of COVID-19 patients, and some patients can still be tested positive for fecal nucleic acid after negative testing for pathogen nucleic acid in respiratory samples. Crowds are generally susceptible. Children and infants also have the disease, but the disease is mild.

Clinical Characteristics and Diagnostics

(i) Clinical characteristics

The incubation period is 1 to 14 d, mostly 3 to 7 d, with an average of 6.4 d. To fever, fatigue, dry cough as the main performance. Can be accompanied by runny nose, sore throat, chest tightness, vomiting and diarrhea and other symptoms. Some patients had mild symptoms, and a few had no symptoms or pneumonia.

The elderly and those with diabetes, hypertension, coronary atherosclerosis heart disease, extreme obesity and other underlying diseases are prone to develop into severe illness after infection. Some patients develop symptoms such as breathing difficulties 1 week after onset of the disease, and severe cases can progress to acute respiratory distress syndrome (acute respiratory distress syndrome, ARDS) and multi-organ functional impairment. The time to progress to critical illness is approximately 8.5 d.

It is worth noting that heavy, critical patients can have low to medium heat in the course of the disease, or even no obvious fever. Most patients have a good prognosis, with deaths mostly in the elderly and those with chronic underlying diseases.

Early CT examination is characterized by multiple small patches or grinding glass shadows, the inner texture can be meshed strip-shaped thick shadow, with the lung band obvious. A few days later the lesions increased, the scope expanded, a wide range of double lung, multiple grinding glass shadow or immersion lesions, part of the lung real change, often bronchial inflatable signs, chest fluid is rare. A small number of patients progressed rapidly, with the change in imaging reaching a peak in the 7th to 10th day of the course. Typical "white lung" performance is rare. After entering the recovery period, the lesions are reduced, the scope is reduced, the oozing lesions are absorbed, some of the fibrous slats appear, and some patients can be completely absorbed.

The total number of peripheral white blood cells in patients with early onset was normal or decreased, the lymphocyte count decreased, some patients could have abnormal liver function, lactic acid dehydrogenase, myosise and myoglobin levels increased; In most patients, CRP and ESR levels were elevated and calcium-lowering levels were normal. In severe cases, d-dipolymer levels increased, other blood clotting indicators abnormal, lactic acid levels increased, peripheral blood lymphocytes and CD4-T lymphocytes for sexual reduction, as well as electrolyte disorders, acid-base imbalance, etc., to metabolic alkali poisoning is more common. Elevated levels of inflammatory cytokines (e.g. IL-6, IL-8, etc.) can occur during the progression of the disease.

(ii) Diagnostic criteria

1. Suspected cases:

Combined with the following comprehensive analysis of epidemiological history and clinical manifestations. Any one of the epidemiological history that meets any 2 of clinical manifestations, or 3 of which have no clear epidemiological history but are consistent with clinical manifestations, are diagnosed as suspected cases.

(1) Epidemiological history: 14 d before the onset of the disease in Wuhan City and surrounding areas, or other case-reported community travel history or residence history;

(2) Clinical manifestations: fever and/or respiratory symptoms; with the above-mentioned new coronavirus pneumonia imaging characteristics; the total number of white blood cells in the early stages of the disease is normal or decreased, and lymphocytes count decreased.

2. Confirmed cases:

A person with one of the following pathogenic evidence is diagnosed as a confirmed case.

(1) Real-time fluorescent reverse transcription PCR test 2019-nCoV nucleic acid positive.

(2) Viral gene sequencing found homologous with known 2019-nCoV height.

(3) In addition to nasopharyngeal swabs, it is recommended to leave sputum as far as possible, the implementation of tracheal intubation patients can collect lower respiratory secretions sent to viral nucleic acid detection.

(iii) Differential diagnosis

Mainly with influenza virus, para-flu virus, adenovirus, respiratory syncytial virus, rhinovirus, human lung virus, severe acute respiratory syndrome (severe acute respiratory syndrome, SARS) coronavirus and other known viral pneumonia identification, with pneumonia mycoplasma, chlamydia pneumonia and bacterial pneumonia identification.

In addition, it is necessary to identify with non-infectious diseases, such as vasculitis, dermatitis and other connective tissue diseases caused by pulmonary lesions and metastivis.

(4) Clinical type

1. Light:

Clinical symptoms were mild, and imaging examination did not show pneumonia.

2. Normal:

With fever, respiratory tract and other symptoms, imaging examination can be seen pneumonia performance.

Early warning of severe illness in common patients should be strengthened. Based on the current clinical research, the elderly (age 65 years old), accompanied by basic diseases, CD4-T lymphocytes 250 / sl, blood IL-6 levels significantly increased, 2 to 3 d pulmonary imaging examination found significant progress of lesions , lactic dehydrogenase (lactic dehydrogenase, LDH) , 2 times the normal value limit, hetic acidity 3 mmol/

3. Heavy:

Conforms to any of the following.

(1) The appearance of shortness of breath, breathing frequency of 30 times / min;

(2) In the state of rest, the oxygen saturation of the arterial blood (arterial oxygen saturation, SaO2) is 93%;

(3) Arterial blood oxygen fractionpressure (arterial partial pressure of oxygen, PaO2)/oxygen concentration (inspired oxygen, FiO2) s 300 mmHg (1 mmHg s.133 kPa). High altitude (over 1,000 m) areas should be corrected for PaO2/FiO2 in accordance with the following formula: PaO2/FiO2 x (mmHg)/760).

Lung imaging examination showed that 24 to 48 h internal lesions significantly progress . . . 50% of the people were managed by heavy duty.

4. Critical type:

Those who meet any of the following can be judged to be critical.

(1) respiratory failure, and the need for mechanical ventilation;

(2) The appearance of shock;

(3) Combining other organ failure, ICU monitoring treatment is required.

(v) Clinical monitoring

Dynamic monitoring of patients' clinical performance, vital signs, fluid inandance, gastrointestinal function and mental state are monitored daily.

Dynamic monitoring of oxygen saturation of the end of the blood in all patients is monitored.

For patients with severe and critical conditions, blood gas analysis was carried out in a timely manner according to changes in the condition; blood routine, electrolyte, CRP, calcite, LDH, clotting function indicators, blood lactic acid, etc., at least 1 test per 2 d; liver function, renal function, ESR, IL-6, IL-8, lymphocyte subgroup, at least 1 test per 3 d; chest imaging examination, usually 1 test per 2 d.

For ARDS patients, a routine ultrasound of the heart and lungs next to the bed is recommended to observe the parameters of the extravascular pulmonary water and heart. In vitro membrane pulmonary oxygenation (extracorporeal membrane oxygenation, ECMO) patient monitoring refers to the implementation section of ECMO.


(i) Antiviral therapy

Can be tried hydroxychloroquine or chlorpyrifos phosphate oral, abidore oral, interferon atomized inhalation, preferred interferon. It is not recommended to use 3 or more antiviral drugs at the same time. The virus nucleic acid should be deactivated in time after the virus nucleic acid has turned negative. The efficacy of all antiviral drugs has yet to be evaluated in further clinical studies.

For patients with positive nucleic acid for heavy and critical viral nucleic acids, the recovery stage plasma may be trialled. Detailed operation and management of adverse reactions refer to the National Health And Health Commission issued by the National Health Commission of the "new coronary pneumonia rehabilitation plasma clinical treatment plan" (trial first edition) . Infusion within 14 d may be more effective, in the later stages of the course, if the continuous detection of viral nucleic acids, can also be trialled in the recovery period plasma treatment.

(ii) Treatment of light and general patients

Support treatment needs to be strengthened to ensure adequate heat, attention to water, electrolyte balance, maintain internal environmental stability, close monitoring of patients' vital signs and oxygen saturation. Timely and effective oxygen therapy measures. Antibacterial drugs and glucocorticoids are not used in principle.

Patients need to be closely monitored, and if there is a significant progression and a risk of becoming serious, comprehensive measures are recommended to prevent the disease from progressing to a heavy level, with caution as appropriate (see the application section of glucocorticoids). Heparin anticoagulant and high-dose vitamin C treatment is recommended. Low-molecular heparin 1 to 2 /d, continued until the patient's D-diipolymer level returned to normal. Once the fibrin degradation product (fibrino degradation product, FDP) is 10 sg/mL and/or D-diipolymer s.5 sg/mL, use ordinary heparin anticoagulant. Vitamin C 50 to 100 mg/kg per day, intravenous drips, continuous use time to oxygenation index significantly improved as the goal.

If there is progress in lung lesions, it is recommended to apply high-dose broad-spectrum protease inhibitors of 60 to 1 million units/d, continuing to improve the imaging examination of the lungs. Intermittent short-short-term blood filtration (intermittent short veno-venuous hemofiltration, ISVVH) is recommended in the event of a cytokine storm.

(iii) The function of organs in critically ill patients supports treatment

1. Protection and maintenance of the cycle function:

The principle of early active control rehydration is implemented. It is recommended to assess effective capacity and initiate fluid therapy as soon as possible after admission. Heavy-duty patients can choose intravenous pathways or through colon pathways for fluid resuscitation. The supplementary liquid is preferred lactic acid ringer.

For vascular active drugs, norepinephrine combined with dopamine is recommended to maintain vascular tension and increase heart displacement. For patients with shock, norepinephrine is preferred, and it is recommended to start using small doses of vascularly active drugs at the same time as fluid resuscitation to maintain circulatory stability and avoid excessive fluid infusion.

Heavy, critically critical patients are recommended to use heart-protecting drugs and to avoid sedatives that inhibit the heart. Isopropyl epinephrine can be used in patients with sinustal tashimitosy. It is recommended that for patients with sinus heart rhythm, heart rate of 50 times/min and hemodynamic instability, intravenous pumping of small doses of isopropyl epinephrine or dopamine to maintain heart rate at about 80 times/min.

2. Reduce inflammation of the pulmonary ito:

2019-nCoV causes severe pulmonary interstitial lesions that can cause lung function deterioration, and high-dose broad-spectrum protease inhibitors are recommended.

3. Protection of kidney function:

Early and reasonable anticoagulant therapy and appropriate liquid therapy are recommended. See the section on the prevention and treatment of cytokine storms, the protection and maintenance of cycling functions.

4. Protection of intestinal function:

Bionics can be used to improve the intestinal microecology of patients. Use raw yellow (15 to 20 g plus 150 ml of warm boiling blisters) or large gas soup or enemas.

5. Nutritional support:

Preferred gastrointestinal nutrition, through nasal feeding or through the empty intestine. The preferred whole protein nutrition preparation is 25 to 35 kcal/kg per day (1 kcal x 4.184 kJ).

6. Prevention and control of cytokine storms:

High doses of vitamin C and ordinary heparin anticoagulant are recommended. High doses of vitamin C are intravenously injected 100 to 200 mg/kg per day. Continuous use time is aimed at a significant improvement in oxygenation index. It is recommended to apply high-dose broad-spectrum protease inhibitors, given 1.6 million units per 8 h 1 time, in a mechanical ventilation state, when the oxygenation index of 300 mmHg can be reduced to 1 million units/d. Anticoagulant therapy can be used to protect endothelial cells and reduce cytokine release, FDP s 10 sg/mL and/or D-diipolymers s5 sg/mL to ordinary heparin (3 to 15 IU/kg per hour) anticoagulant. The patient's clotting function and platelets must be reviewed at 4 h after first use of heparin. With ISVVH, 6 to 10 h per day.

7. Sedative muscle looseness and artificial hibernation therapy:

Patients with mechanical ventilation or receiving ECMO need to be sedated on an algemotheic basis. For patients with severe human-machine resistance when establishing artificial airways, it is recommended to apply small doses of muscle loose medicine for short-range use. Hibernation therapy is recommended for patients with oxygenation index of 200 mmHg.

Artificial hibernating therapy can reduce the body's metabolism and oxygen consumption, while expanding blood vessels in the lungs and significantly improve oxygenation, it is recommended to use continuous intravenous injection of the method of medication, the patient's blood pressure needs to be closely monitored.

Be careful with opioids and right metamida. Due to the presence of severe patients with abnormal LEVELs of IL-6 and easy to lead to bloating, should avoid the use of opioids, and 2019-nCoV can inhibit the function of sinus and the occurrence of sinus tachycardia, so should be careful lying with the heart inhibited sedatives. In order to prevent the occurrence and aggravation of lung infection, try to avoid excessive sedation for a long time, the condition should be allowed to withdraw the muscle loose medicine as soon as possible. It is recommended to closely monitor the depth of sedation.

8. Oxygen therapy and breathing support:

(1) nasal catheter or mask oxygen therapy, restand air conditions SaO2 , or after the activity SaO2 90%, or oxygenation index (PaO2/FiO2) for 200 to 300 mm Hg; accompanied or not accompanied by respiratory distress;

(2) by nasal high-flow oxygen therapy (high-flow nasal cannula oxygen therapy, HFNC), receiving nasal catheteror or mask oxygenation 1 to 2 h oxygenation does not meet the treatment requirements, breathing distress does not improve;

(3) Non-invasive positive pressure ventilation (non-invasive positive ventilation, NPPV), receiving HFNC 1 to 2 h oxygenation is not effective at treatment, no improvement in respiratory distress; or in the course of treatment hypoxemia and/or respiratory distress increased; or oxygenation index of 150 to 200 mmHg;

(4) When there is invasive mechanical ventilation, receiving HFNC or NPPV treatment 1 to 2 h oxygenated does not meet the treatment requirements, breathing distress does not improve, or in the course of treatment hypoxemia and/or respiratory distress aggravated, or oxygenation index 150 mm Hg, should be considered for invasive ventilation. A protective ventilation strategy with low tide air volume (4 to 8 mL/kg ideal mass) as the core is preferred.

9. Implementation of ECMO:

An ECMO may be considered if one of the following conditions is met.

(1) PaO2/FiO2 50 mmHg more than 1 h;

(2) PaO2/FiO2 80 mmHg exceeds 2 h; (3) arterial blood pH of 7.25 and accompanied by PaCO2 60 mmHg more than 6 h. THE ECMO MODE PREFERRED INTRAVENOUS-VENVEAL ECMO.

(4) Special problems in treatment and treatment

1. Application of glucocorticoids:

Caution should be used with glucocorticoids. Imaging examination suggests that there is significant progress in pneumonia, resting in the state of non-oxygen patients SaO2 , 93% or shortness of breath (breathing frequency of 30 times / min) or oxygenation index of 300 mmHg, especially the progressof the disease significantly accelerated, in the face of intubation risk can be added to the glucocorticoid.

Patients are advised to withdraw their use of glucocorticoids quickly when intubation or ECMO support can maintain effective blood oxygen concentrations. For non-severe patients using metastasis nylon, the recommended dose is controlled at 20 to 40 mg/d, severe patients control at 40 to 80 mg/d, the course of treatment is generally 3 to 6 d. Depending on the body mass discretion, the amount of increase or decrease.

2. Use of immunomodulating drugs:

Injection of thymus peptides twice a week has some effect on improving the immune function of patients, preventing severe illness and shortening the detox time. Due to the lack of specific antibodies, the use of intravenous human immunoglobulin therapy in large doses is not currently supported. However, some patients have low lymphocyte levels and are at risk of combining other viral infections, and can infuse human immunoglobulin 10 g/d intravenously, with a course of 3 to 5 d.

3. Precise diagnosis and treatment of combined bacterial and fungal infections:

Clinical microbiological monitoring of all critically ill and critically ill patients. Every day to take the patient's sputum and urine for culture, high fever patients in a timely blood culture. All suspected sepsis patients with an vascular catheter should be sent to the peripheral peripheral venous blood culture and catheter blood culture at the same time. All suspected sepsis patients may consider collecting peripheral blood for germological molecular diagnostic examination, including PCR-based molecular biology testing and second-generation sequencing.

Elevated levels of calcitonin were indicative for the diagnosis of sepsis/sepsis shock. When the condition of the new coronavirus pneumonia worsens, there is an increase in THE level of CRP, and the increase of CRP level is not specific to the diagnosis of sepsis caused by bacterial and fungal infections.

Critically ill patients with open airways tend to be prone to bacterial and fungal infections later in life. If sepsis occurs, empirical anti-infection treatment should be given as soon as possible. For patients with septic shock, empirical antimicrobials can be combined before obtaining an pathogen diagnosis, while covering the most common e. coli, staphylococcal and enterococci infections. Infected persons who occur after hospitalization may be able to use beta-lactamase inhibitor complexes.

If the treatment effect is not good, or the patient is severe infectious shock, can be replaced with carbon penicillin drug treatment. If you consider the combination of enterococci and staphylococcus infection, can be added to the glycopeptide drug (vancomycin) for empirical treatment, blood flow infection optional dattomycin, lung infection-based can be selected linazine.

Attention should be paid to catheter-related infections in critically ill patients, and the treatment should be empirically covered with staphylococcus staphylococcus resistant to methicillin. Empirical treatment with glycopeptide drugs (vancomycin) is optional.

Candida infection is also more common in critically ill patients, if necessary, experience coverage candidatreatment, can be added to the drug echiconobacteria.

As the length of hospital stay for seriously ill patients increases, drug-resistant infections are gradually increasing, and the use of antimicrobialdrugs must be adjusted according to drug-sensitive tests.

4. Hospital infection prevention and control:

(1) According to the 2019 National Health and Health Commission "Basic System for Infection Prevention and Control of Medical Institutions (Trial)" ( 13), actively implement evidence-based infection prevention and control cluster intervention strategy, effective prevention of ventilator-related pneumonia, intravascular catheter-related blood flow infection, catheter-related urinary tract infection, carbon penicillin drug-resistant grameel-negative bacillus and other multi-drug-resistant bacteria and fungal infections.

(2) Strictly comply with the requirements of the National Health and Health Commission's Technical Guide for the Prevention and Control of New Coronary Virus Infections in Medical Institutions (First Edition) "Guidelines on the Use of Common Medical Protection Supplies in The Prevention and Control of New Coronary Virus Infections (Trial)" "Technical Guidelines for the Protection of Medical Personnel during the Outbreak of New Coronary Pneumonia (Trial)" 5,16), strengthen the process management, the correct selection and use of masks, isolation clothing, protective clothing, eye masks, protective masks, gloves and other personal protective supplies, strict implementation of disinfection and isolation measures, to minimize the risk of hospital infection, to eliminate medical personnel in the hospital 2019-nCoV infection.

5. Treatment of infants and young children:

Light children only need oral administration. In addition to oral administration of the disease in ordinary children, dialectical Chinese medicine treatment may be considered. If a bacterial infection is combined, an antibacterial drug can be added. Critically ill children are mainly supported by the treatment of the disease, the experience of the libavirin injection antiviral treatment, 15 mg/kg (2 times/d), the course of treatment does not exceed 5 d.

(5) The combination of Chinese and Western medicine treatment schemes

The combination of Chinese and Western medicine to treat the new coronavirus pneumonia can improve the synergistic effect.

For adult patients, the condition can be improved by dialectical treatment of Chinese medicine. For light patients, the certificate is that the person who is a wind-hot witness gives the chinese medicine silver warp plus subtraction treatment, mainly gastrointestinal symptoms, the proof is wet to stop Weiyang to give the pupu xia soup, three ren Tonga minus.

For ordinary patients, the certificate is hot evil lung, to give chinese medicine hemp apricot gantonga reduction; For heavy patients, if the fever does not retreat, even high fever, bloating, feces dry closed knot, the evidence is a hot poison closed lung, to give Chinese medicine large gas soup enema to pass through the diarrhea fever, so that the fever is reduced or heat back, can also be used Chinese medicine white tiger soup, lifting and dispersing and xuan white gas Tonga reduction treatment, so as to cut off the disease, reduce the occurrence of heavy to critical type.

Children light patients, the evidence of the time-borne disease guard, can be used silver warp or incense sanois plus and minus. Ordinary type of children, wet hot closed lung, to give the apricot soup three ren Tonga reduction;

Heavy patients if the epidemic poisonclosed lungs (currently rare in the country) can refer to adultXuanBai gas soup with ganlu disinfection Tanga minus;

(6) Discharge criteria

At the same time, those who meet the following conditions may consider being discharged from the hospital:

(1) The body temperature is back to normal . . . 3 d;

(2) The respiratory symptoms improved significantly;

(3) Lung imaging examination showed a significant improvement in acute oozing lesions;

(4) Two consecutive respiratory specimen nucleic acid test negative (sampling time at least 1 d interval);

(5) After the respiratory sample nucleic acid test is negative, the fecal pathogen nucleic acid test is also negative;

(6) The total course of the disease is more than 2 weeks.

(7) Health management of discharged patients

1. For discharged patients, close follow-up should still be made. Follow-up is recommended in the 2nd and 4th weeks after the patient is discharged from the hospital to the designated follow-up clinic.

2. When a patient is discharged from the hospital, he or she should be clear about his/her place of residence and address in the city.

3. Patients stay at home for 2 weeks after discharge from hospital, avoid activities in public places, must wear a mask when they go out.

4. According to the patient's address (including hotels or hotels), the relevant district health and health committee organized by the corresponding medical institutions to do a good job of health management. For 2 weeks, professionals will be able to measure a patient's temperature twice a day, ask about their health status, and conduct health education.

5. If fever and/or respiratory symptoms occur again, the corresponding medical institution shall promptly report to the District Health and Health Commission, District Centers for Disease Control and Prevention, and assist in sending the designated medical institutions within the jurisdiction for medical treatment.

6. District Health Committee, District Centerfor for Disease Control and Prevention received the report, timely report to the higher authorities.

Members of the Expert Group

Writing experts (in order of last name pinyin): Yu Yuan (Severe Medical Department of Renji Hospital affiliated with Shanghai Jiaotong University School of Medicine), Hu Bijie (Infection Department of Zhongshan Hospital affiliated with Fudan University), Li Feng (Respiratory Medicine, Shanghai Public Health Clinical Center), Li Xin (Cardiosurgery/ECMO Treatment of Sun Yat-sen Hospital affiliated with Fudan University) Center), Li Yingchuan (The Anesthesiology Department of the Sixth People's Hospital affiliated with Shanghai Jiaotong University), Lu Hongzhou (Infection and Immunology Department of Shanghai Public Health Clinical Center), Mao Enqiang (Emergency Department of Ruijin Hospital, Shanghai Jiaotong University Medical College), Yu Hongping (Severe Medical Department of Ruijin Hospital, Shanghai Jiaotong University Medical College), Shi Kehua (Respiratory Department of Chinese Medicine Hospital affiliated with Shanghai University of Traditional Chinese Medicine), Wang Wei (Lung Circulation Department of Shanghai Lung Hospital affiliated with Tongji University), Wang Qibing (Testing Department of Zhongshan Hospital affiliated with Fudan University), Wang Sheng (Emergency Critical Care Department of the Tenth People's Hospital affiliated with Tongji University), Yu Kanglong (Shanghai Jiaotong University Affiliated No. First People's Hospital Emergency and Critical Care Department, Zeng Mei (Hospital Infection Department affiliated with Fudan University), Zhang Wei (Respiratory Department of Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine), Zhang Wenhong (Hospital Infection Department of Huashan Hospital affiliated with Fudan University), Zhu Duming (Severe Medical Department of Sun Yat-sen Hospital affiliated with Fudan University), Zhu Lei (Respiratory Department of Sun Yat-sen Hospital affiliated with Fudan University)

Consult an expert (sorted by last name pinyin):

Li Qiang (Respiratory Department of Oriental Hospital affiliated with Tongji University), Li Xiangyang (Respiratory Department of East China Hospital affiliated with Fudan University), Yu Jieming (Respiratory Department of Ruijin Hospital affiliated with Shanghai Jiaotong University School of Medicine), Song Yuanlin (Respiratory Department of Zhongshan Hospital affiliated with Fudan University), Tian Rui (Critical Department of First People's Hospital affiliated with Shanghai Jiaotong University), Wang Xingpeng (Shanghai Shenkang Hospital Development Center), Wu Yinggen (Longhua Hospital affiliated with Shanghai University of Traditional Chinese Medicine), Xu Jinfu (Respiratory Department of Shanghai Lung Hospital affiliated with Tongji University), Xu Jie (Infection Department of the Ninth People's Hospital affiliated with Shanghai Jiaotong University Medical College), Zhang Huiyong (Lung Department of Longhua Hospital affiliated with Shanghai University of Traditional Chinese Medicine), Zhu Tongyu (Urology, Shanghai Public Health Clinical Center), Zhu Yuchen (Emergency Department, Huashan Hospital, Affiliated with Fudan University)

Conflicts of interest 

All authors declare that there is no conflict of interest

References (slightly)








上海救治专家组 SIFIC感染循证资讯 6 days ago


2019冠状病毒病(corona virus disease 2019, COVID-19)于2019年12月31日首次在湖北省武汉市被报告[1,2]。COVID-19作为呼吸道传染病,已被纳入《中华人民共和国传染病防治法》规定的乙类传染病,按甲类传染病管理。



2019新型冠状病毒(2019 novel coronavirus,2019-nCoV)是属于β属的新型冠状病毒。2020年2月11日,国际病毒分类委员会(The International Committee on Taxonomy of Viruses,ICTV)将该病毒命名为严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)[4]。




潜伏期为1~14 d,多为3~7 d,平均为6.4 d。以发热、乏力、干咳为主要表现。可伴有流涕、咽痛、胸闷、呕吐和腹泻等症状。部分患者症状轻微,少数患者无症状或无肺炎表现。

老年人及患有糖尿病、高血压、冠状动脉粥样硬化性心脏病、极度肥胖等基础疾病者感染后易发展为重症。部分患者在发病后1周出现呼吸困难等症状,严重者可进展为急性呼吸窘迫综合征(acute respiratory distress syndrome,ARDS)及多器官功能损伤。进展至重症的时间约为8.5 d。







①流行病学史:发病前14 d内有武汉市及周边地区,或其他有病例报告社区的旅行史或居住史;发病前14 d内与2019-nCoV感染(核酸检测阳性)者有接触史;发病前14 d内曾接触过来自武汉市及周边地区,或来自有病例报告社区的发热或有呼吸道症状的患者;聚集性发病。








主要与流行性感冒病毒、副流感病毒、腺病毒、呼吸道合胞病毒、鼻病毒、人偏肺病毒、严重急性呼吸综合征(severe acute respiratory syndrome,SARS)冠状病毒等其他已知病毒性肺炎鉴别,与肺炎支原体、衣原体肺炎和细菌性肺炎等鉴别。







应加强普通型患者重症化的早期预警。基于目前的临床研究表明,老年(年龄>65岁),伴有基础疾病,CD4+T淋巴细胞数<250/µL,血IL-6水平明显上升,2~3 d肺部影像学检查发现病灶明显进展>50%,乳酸脱氢酶(lactic dehydrogenase,LDH)>2倍正常值上限,血乳酸≥3 mmol/L,代谢性碱中毒等均是重症化的早期预警指标[8]。




②在静息状态下,指动脉血氧饱和度(arterial oxygen saturation,SaO2)≤93%;

③动脉血氧分压(arterial partial pressure of oxygen,PaO2)/吸氧浓度(fraction of inspired oxygen,FiO2)≤300 mmHg(1 mmHg=0.133 kPa)。高海拔(海拔超过1 000 m)地区应根据以下公式对PaO2/FiO2进行校正:PaO2/FiO2×[大气压(mmHg)/760]。

肺部影像学检查显示24~48 h内病灶明显进展>50%者按重型管理。









对于重症及危重症患者,根据病情变化及时进行血气分析;血常规、电解质、CRP、降钙素原、LDH、凝血功能指标、血乳酸等,每2 d至少检测1次;肝功能、肾功能、ESR、IL-6、IL-8、淋巴细胞亚群,每3 d至少检测1次;胸部影像学检查,通常情况下每2 d检查1次。

对于ARDS患者,建议常规行床旁心脏和肺的超声检查,观察其血管外肺水和心脏的参数。体外膜肺氧合(extracorporeal membrane oxygenation,ECMO)患者监测参照ECMO的实施章节。




对于重型和危重型病毒核酸阳性患者,可试用康复者恢复期血浆。详细操作及不良反应管理参照国家卫生健康委颁布的《新冠肺炎康复者恢复期血浆临床治疗方案》(试行第一版)[3]。起病14 d内予以输注可能疗效更好,在病程后期如持续检出病毒核酸,也可试用康复者恢复期血浆治疗。



需密切观察患者病情变化,若病情出现显著进展并有转为重型风险时,建议采取综合措施阻止疾病进展为重型,可酌情谨慎使用低剂量短程糖皮质激素(具体方案见糖皮质激素的应用章节)。推荐使用肝素抗凝和大剂量维生素C治疗[9,10]。低分子肝素1~2支/d,持续至患者D-二聚体水平恢复正常。一旦纤维蛋白降解产物(fibrinogen degradation product,FDP)≥10 µg/mL和(或)D-二聚体≥5 μg/mL,则改用普通肝素抗凝。维生素C每天50~100 mg/kg,静脉滴注,持续使用时间以氧合指数显著改善为目标。

如出现肺部病灶进展,推荐应用大剂量广谱蛋白酶抑制剂60~100万单位/d,持续至肺部影像学检查改善。一旦出现"细胞因子风暴",建议采用间断短时血液滤过(intermittent short veno-venuous hemofiltration,ISVVH)[11]。











可使用益生元改善患者肠道微生态。使用生大黄(15~20 g加150 ml温开水泡制)或大承气汤口服或灌肠。


首选胃肠内营养,经鼻饲或经空肠途径。首选整蛋白营养制剂,能量为每天25~35 kcal/kg(1 kcal=4.184 kJ)。


推荐使用大剂量维生素C和普通肝素抗凝。大剂量维生素C每天100~200 mg/kg静脉注射。持续使用时间以氧合指数显著改善为目标。推荐应用大剂量广谱蛋白酶抑制剂,给予160万单位,每8 h 1次,在机械通气状态下,当氧合指数>300 mmHg时可减量至100万单位/d。可采取抗凝治疗保护内皮细胞与减少细胞因子释放,FDP≥10 µg/mL和(或)D-二聚体≥5 μg/mL时予普通肝素(每小时3~15 IU/kg)抗凝。初次使用肝素后4 h必须复查患者凝血功能和血小板。采用ISVVH,每天6~10 h。


机械通气或接受ECMO患者需在镇痛基础上镇静。对于建立人工气道时有严重人机对抗的患者,建议短程应用小剂量肌松药物。建议氧合指数<200 mmHg的重症患者可采用冬眠疗法。




①鼻导管或面罩氧疗,静息吸空气条件下SaO2≤93%,或活动后SaO2<90%,或氧合指数(PaO2/FiO2)为200~300 mmHg;伴或不伴呼吸窘迫;均推荐持续氧疗。

②经鼻高流量氧疗(high-flow nasal cannula oxygen therapy,HFNC),接受鼻导管或面罩氧疗1~2 h氧合达不到治疗要求,呼吸窘迫无改善;或治疗过程中低氧血症和(或)呼吸窘迫加重;或氧合指数为150~200 mmHg;推荐HFNC。

③无创正压通气(noninvasive positive pressure ventilation,NPPV),接受HFNC 1~2 h氧合达不到治疗效果,呼吸窘迫无改善;或治疗过程中低氧血症和(或)呼吸窘迫加重;或氧合指数为150~200 mmHg时;可以选用NPPV。

④有创机械通气,接受HFNC或NPPV治疗1~2 h氧合达不到治疗要求,呼吸窘迫无改善;或治疗过程中低氧血症和(或)呼吸窘迫加重;或氧合指数<150 mmHg时;应考虑有创通气。首选以小潮气量(4~8 mL/kg理想体质量)为核心的保护性通气策略。



① PaO2/FiO2< 50 mmHg超过1 h;

② PaO2/FiO2<80 mmHg超过2 h;

③动脉血pH值<7.25并伴有PaCO2>60 mmHg超过6 h。ECMO模式首选静脉-静脉ECMO。



需谨慎使用糖皮质激素。影像学检查提示肺炎出现明显进展,静息未吸氧状态下患者SaO2≤93%或呼吸急促(呼吸频率≥30次/min)或氧合指数≤300 mmHg,特别是病情进展速度明显加快,面临插管风险时可加用糖皮质激素。

患者在插管或ECMO支持可维持有效血氧浓度时,则建议迅速撤退糖皮质激素的使用。对于非重症患者使用甲泼尼龙,建议剂量控制在20~40 mg/d,重症患者控制在40~80 mg/d,疗程一般为3~6 d。可根据体质量酌量增减[12]。


每周2次皮下注射胸腺肽,对提高患者免疫功能、阻止病情重症化、缩短排毒时间有一定效果。由于缺乏特异性抗体,目前不支持大剂量使用静脉输注人免疫球蛋白治疗。但部分患者淋巴细胞水平低下,且有合并其他病毒感染的风险,可静脉输注人免疫球蛋白10 g/d,疗程为3~5 d。













轻型患儿仅需对症口服给药治疗。普通型患儿除对症口服给药治疗外,可考虑辨证中药治疗。若合并细菌感染,可加用抗菌药物。重危患儿以对症支持治疗为主,经验给予利巴韦林注射剂抗病毒治疗,15 mg/kg(2次/d),疗程不超过5 d。









①体温恢复正常>3 d;



④连续两次呼吸道标本核酸检测阴性(采样时间至少间隔1 d);

















No comments yet

License Information

Oops! License is not active yet


Your website license was not activated yet or license has expired.

Try again

  • If your website was working, and now it's not, please contact your webhosting company. It's the company you pay for ths website, domain or hosting
  • If your website was not working yet, you probably have no license. You can contact your webhosting company for assistance, or get a license on your own
    Sign In Get an Domain License